Just had a peruse of this, IMO forget about the data and concerns of the FDA...even if one assumes that FDA approval will be received there are the grand total of 250 to 300 new cases of CML patients diagnosed with the T315I mutation per annum in the entire US. (See paragraph 3 page 7)
Has anyone crunched some of the numbers here?
Rgds
Prof
- Forums
- ASX - By Stock
- CXS
- omapro addressable market size
omapro addressable market size
-
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CXS (ASX) to my watchlist
Currently unlisted public company.